A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may have disease modifying effects when used early in the course of disease.

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia (ITP) by 45%, according to data ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...

Tune in to a powerful episode of the AscellaHealth Podcast Pulse, released in recognition of Rare Disease Awareness Month. Hosted by Gabriella Patone of AscellaHealth, this special edition features an ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with ...